Stokes Family Office’s Opus Genetics IRD Stock Holding History

Stokes Family Office’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49.8K	Hold	12,120	–	–	0.01%	272
2026 Q1	$55.1K	Hold	12,120	–	–	0.01%	276
2025 Q4	$24.4K	Hold	12,120	–	–	﹤0.01%	310
2025 Q3	$20K	Hold	12,120	–	–	﹤0.01%	265
2025 Q2	$11.4K	Hold	12,120	–	–	﹤0.01%	234
2025 Q1	$11.9K	Hold	12,120	–	–	﹤0.01%	233
2024 Q4	$14.4K	Hold	12,120	–	–	﹤0.01%	244
2024 Q3	$15.9K	Hold	12,120	–	–	﹤0.01%	227
2024 Q2	$18.5K	Hold	12,120	–	–	﹤0.01%	223
2024 Q1	$24.4K	Hold	12,120	–	–	﹤0.01%	222
2023 Q4	$36.5K	Sell	12,120 -910	-7%	-$2.69K	﹤0.01%	221
2023 Q3	$43.7K	Buy	13,030 +780	+6%	+$3.13K	0.01%	338
2023 Q2	$53.2K	Buy	12,250 +130	+1%	+$617	0.01%	327
2023 Q1	$45.5K	Hold	12,120	–	–	0.01%	300
2022 Q4	$42.8K	Hold	12,120	–	–	0.01%	274
2022 Q3	$24K	Hold	12,120	–	–	﹤0.01%	271
2022 Q2	$23K	Hold	12,120	–	–	﹤0.01%	271
2022 Q1	$39K	Hold	12,120	–	–	0.01%	257
2021 Q4	$45K	Hold	12,120	–	–	0.01%	249
2021 Q3	$62K	Hold	12,120	–	–	0.01%	226
2021 Q2	$64K	Hold	12,120	–	–	0.01%	217
2021 Q1	$70K	Buy	+12,120	New	+$113K	0.01%	194

Other funds holding IRD

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stokes Family Office's IRD Position: Q2 2026 in Review

Stokes Family Office held its Opus Genetics (IRD) position steady in Q2 2026 at 12,120 shares worth $49.8K. The position accounts for 0.01% of the portfolio, ranked #272.

Stokes Family Office first reported a position in IRD in Q1 2021 and has held it in 22 quarters since. The position peaked at $70K in Q1 2021. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

Stokes Family Office held 12,120 shares of Opus Genetics worth $49.8K as of Q2 2026.
Stokes Family Office left its Opus Genetics share count unchanged in Q2 2026.
Opus Genetics made up 0.01% of Stokes Family Office's portfolio in Q2 2026, its #272 holding.
Stokes Family Office first reported a position in Opus Genetics in Q1 2021 and has held it in 22 quarters since.
Stokes Family Office's Opus Genetics position peaked at $70K in Q1 2021.
103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Stokes Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.